1 results match your criteria: "Beth Israel Deaconess Medical Center and; Harvard Medical School[Affiliation]"
Atazanavir plus ritonavir or efavirenz as part of a 3-drug regimen for initial treatment of HIV-1.
Ann Intern Med
April 2011
Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center, 1124 West Carson Street, N-24, Torrance, CA 90502, USA.
Background: Limited data compare once-daily options for initial therapy for HIV-1.
Objective: To compare time to virologic failure; first grade-3 or -4 sign, symptom, or laboratory abnormality (safety); and change or discontinuation of regimen (tolerability) for atazanavir plus ritonavir with efavirenz-containing initial therapy for HIV-1.
Design: A randomized equivalence trial accrued from September 2005 to November 2007, with median follow-up of 138 weeks.